14th ICID - Poster Abstracts - International Society for Infectious ...

When citing these abstracts please use the following reference:
Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number.
Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1
is available electronically on http://www.sciencedirect.com
Final Abstract Number: 28.042
Session: Influenza
Date: Wednesday, March 10, 2010
Time: 12:30-13:30
Room: Poster & Exhibition Area/Ground Level
Type: Poster Presentation
Prolonged prophylaxis for A H1N1 Influenza pandemic in Oncohematologic patients - Adherence,
security and efficiency.
S. J. Ramirez Borga 1 , A. S. Firpo 2 , L. Lopez 3 , J. J. Napal 3 , M. V. Prates 3 , S. Yantorno 3 , A.
Enrico 3 , J. Milone 3
1 Hospital Italiano de La Plata, La Plata, Buenos Aires, Argentina, 2 Hospital Italiano La Plata, La
Plata, Buenos Aires, Argentina, 3 Hospital Italiano La Plata, La Plata, Argentina
Background: Since 1 May to 31 October 2009, 1,241,612 cases of a kind of Influenza disease
were notified in Argentine. 24,504 virologic samples were processed, confirming that 10,248 were
cases of AH1N1 Influenza, there were 12,471 cases that required hospitalization and 600
confirmed deaths.
Oncohematologic patients were in the high risk group to this infection. As a preventive strategy a
prolonged prophylaxis with oseltamivir was administered during 30 days.
Our objetive was value the adherence, security and efficiency of the prolonged prophylaxis
against AH1N1 Influenza with oseltamivir in an oncohematologic patients cohort.
Methods: From July to September 2009, a prospective study was performed from a cohort of 45
oncohematologic patients above 19 years old, that received a 75 mg daily dose of oseltamivir
during 30 days. Then, by an anonymous survey, age was consulted, as well as sex,
oncohematologic pathology, treatment performance, adverse effects that patients presented,
doses that were used, whether and why medication was interrupted, concomitant medication and
whether the patient had to consult the doctor during that period of time.
Results: Nor Influenza Syndromes were registered in the cohort, neither Influenza cases during
the administration of such prophylaxis. Medium age was 54 years (range 19-87), 22 females and
23 males. Basal diseases were Lymphomas in 42, 2 % of the cases; Acute Leukemias in 24 %;
Multiple Myeloma in 17, 8 %; Hodgkin disease in 11,1 % and Myelodysplasia in 6,7 %.
From 45 patients, 24 (53, 3 %) presented adverse effects, 60 % with digestive symptoms, 18 %
neurologic and 15 % fatigue.
In 34 patients (75, 5 %) a 100 % adherence was achieved. From those patients that did not finish
the treatment, 5 said that it was because they had a digestive intolerance, 3 did not give their
reasons and another one because he/she began late.
No serious adverse effects requiring hospitalization were objectived.
There were 32 patients that were already receiving other medication during antiviral prophylaxis,
and only 6 patients had to consult their doctor during such period of time.
Conclusion: Daily prophylaxis efficiency with oseltamivir was successful in 100 % of the cases.
The adherence to oseltamivir was partial (75,5%) mainly because of digestive intolerance. No
serious adverse effects were detected.